← Back to Search

Sphingosine-1-phosphate receptor modulator

Ocrevus for Multiple Sclerosis

Phase 2 & 3

Waitlist Available

Research Sponsored by Robert Zivadinov, MD, PhD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6, 12, 24 and 36 months

Awards & highlights

Study Summary

This trial is testing whether the drug Mayzent is better than the current standard of care, Ocrevus, at reducing microglial activation in patients with active secondary progressive multiple sclerosis.

Eligible Conditions

Secondary Progressive Multiple Sclerosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6, 12, 24 and 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6, 12, 24 and 36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6, 12, 24 and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change from baseline in PET Activation at 12 Months

Secondary outcome measures

Change from baseline in PET activation at 6,12,24 and 36 months between Mayzent and active comparator

Number of new ultrasmall superparamagnetic iron oxide particles

Other outcome measures

Absolute change in Hyperintense T2 Lesions volume

Absolute change in Hypo-intense T1 Lesions volume

Neuroglia

+8 more

Trial Design

2Treatment groups

Active Control

Group I: OcrevusActive Control1 Intervention

Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Ocrevus by their neurologist.

Group II: MayzentActive Control1 Intervention

Patients diagnosed with secondary-progressive multiple sclerosis who have been prescribed Mayzent by their neurologist.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Robert Zivadinov, MD, PhDLead Sponsor

State University of New York at BuffaloLead Sponsor

248 Previous Clinical Trials

49,524 Total Patients Enrolled

11 Trials studying Multiple Sclerosis

3,278 Patients Enrolled for Multiple Sclerosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research initiative involve participants that are elderly?

"This particular medical trial is only open to individuals between the legal age of consent and 60 years old. Those younger than 18 can find 80 different clinical studies, while those over 65 have access to 1015 trials."

Answered by AI

What is the current participant count of this research endeavor?

"Affirmative. Clinicaltrials.gov has data that suggests this current medical experiment is actively looking for participants to join the trial, which was first made available on September 27th 2021 and last updated October 10th 2022. The study requires 60 individuals at a single site."

Answered by AI

What risks might be associated with Mayzent treatment?

"There is substantial evidence for the safety of Mayzent, garnering it a score of 3. This drug has already been approved by regulatory agencies and is in Phase 4 trials."

Answered by AI

Is my profile sufficient to qualify me for this experiment?

"A maximum of 60 participants that possess neoplasm metastasis and are between 18 and 60 years old may be admitted to this clinical trial."

Answered by AI

Are researchers actively seeking out participants for this trial?

"According to clinicaltrials.gov, this research is open for recruitment and was posted on the 27th of September 2021 before being most recently revised on October 10th 2022."

Answered by AI

Is this trial a pioneering effort in its field?

"As of now, 31 active clinical trials for Mayzent are being conducted in 390 cities and 64 countries around the world. Genentech, Inc. first initiated studies on this medication back in 2008 with 220 participants; 17 additional assessments have been held since then. The drug has already reached Phase 2 of its approval process."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

Robert Zivadinov, MD, PhD 2021. "Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04925557.